Answers are grounded in this paper and cite their sources.
Although there was no significant difference in the rate of death between patients with shock who were treated with dopamine as the first-line vasopressor agent and those who were treated with norepinephrine, the use of dopamine was associated with a greater number of adverse events. (ClinicalTrials.gov number, NCT00314704.)
No takes yet. Share an insight, caveat, or question.
Backer et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: